



CODEN [USA]: IAJPBB

ISSN : 2349-7750

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

<https://doi.org/10.5281/zenodo.7215510>
Available online at: <http://www.iajps.com>

Review Article

OVERALL REVIEW AND EVALUATION OF PAEDIATRIC ASTHMA

Senthilpandi. K*¹, Swarnapriya.S¹, Ramnath.E¹, Tivyalakshmi.S. T¹, Fathima Basheera.M²

Professor, Department of Pharmacy Practice,
Arulmigu Kalasalingam College of Pharmacy,
Krishnankovil-626126, India.

Article Received: October 2022

Accepted: October 2022

Published: October 2022

Abstract:

Asthma is defined as a habitual seditious complaint of the airways. The habitual inflammation is associated with airway hyperresponsiveness (an inflated airway- narrowing response to specific triggers similar as contagions, allergens and exercise) that leads to intermittent occurrences of gasping, breathlessness, casket miserliness and/ or coughing that can vary over time and in intensity. Viral respiratory tract infections, Exercise, Weather changes in temperature and humidity, Domestic pollutants (eg, pests, mould and dust mites), Environmental pollutants (eg, air pollution), Secondhand smoke exposure, Pets and animals, etc.. are the common factors that triggers asthma in children. Personal or family history of atopy: eczema, allergic rhinitis or nasal polyposis, Family history of asthma, Exposure to secondhand smoke, Preterm birth, Low birth weight, Obesity, Poor housing quality/mould and dampness, Air pollution are the risk factors associated with asthma. The pathophysiology involved in asthma is the infiltration of inflammatory cells (neutrophils, eosinophils, and lymphocytes) into the airway, activation of mast cells, and damage to epithelial cells. These responses leads to airway swelling, increased mucus secretion, and bronchial dysfunction which produce airway flow limitation and asthma symptoms. Paroxysms of dypnoea, intermittent occurrences of gasping, Coughing (particularly at night or in the early morning), casket miserliness and Sleep dislocation are the signs associated with asthma in children. The treatment involved in asthma includes Oxygen for hypoxia, inhaled and oral corticosteroids, leukotriene receptor antagonist, long-acting beta2-agonist, immunoglobulin E.

Key words: Asthma, Inflammation, Airway, IgE, Corticosteroids, Pulmonary function.

Corresponding author:**K. Senthilpandi,**

AKCP,

Krishnan koil, Virudhunagar,

Tamil Nadu-626126

E-Mail-senthilpandi64@gmail.com**Phone No:**9080655917

QR code



Please cite this article in K. Senthilpandi et al, *Overall Review And Evaluation Of Paediatric Asthma.*, Indo Am. J. P. Sci, 2022; 09(10).

INTRODUCTION:

Asthma is defined as a habitual seditious complaint of the airways. The habitual inflammation is associated with airway hyperresponsiveness (an inflated airway- narrowing response to specific triggers similar as contagions, allergens and exercise) that leads to intermittent occurrences of gasping, breathlessness, casket miserliness and/ or coughing that can vary over time and in intensity. Symptom occurrences are generally associated with wide, but variable, tailwind inhibition within the lungs that's generally reversible either spontaneously or with applicable asthma treatment similar as a fast- acting bronchodilator [1]. Exacerbations of asthma are occurrences of progressive increase in briefness of breath, cough, gasping or casket miserliness [2]. Asthma is an seditious complaint of the respiratory tract characterized by intermittent and/ or habitual occurrences of airway inflammation and inhibition (manifested by wheeze or cough, or demonstrated upon pulmonary function testing) and substantiation of reversibility of inhibition [3]. Asthma is a complaint of airways that's characterised by increased responsiveness of the tracheobronchial tree to a variety of stimulants performing in wide gymnasium narrowing of the air passages which may be

relieved spontaneously or by remedy. Asthma is an episodic complaint manifested clinically by paroxysms of dyspnoea, cough and gasping. still, a severe and running form of the complaint nominated status asthmaticus may prove fatal. [4]

ETIOLOGY

Although inheritable predilection is easily apparent, gene- by- terrain commerce presumably explains much of the transnational variation in frequency rates for mislike and asthma. Environmental factors similar as infections and exposure to endotoxins may be defensive or may act as threat factors, depending in part on the timing of exposure in immaturity and nonage. Some antenatal threat factors, including motherly smoking, have been forcefully established, but diet and nutrition, stress, use of antibiotics and mode of delivery may also affect the early development of mislike and asthma. latterly in nonage, apparent threat factors include exposure to allergens, breastfeeding (which may originally cover and also increase the threat of sensitization), family size and structure, and coitus and gender. In majority, rush of nonage asthma may be just as common as new- onset asthma, which may have an occupational base [5].

RISK FACTORS**TABLE:1 COMMON ASTHMA TRIGGERS [6]**

- Viral respiratory tract infections
- Exercise
- Weather changes in temperature and humidity
- Domestic pollutants (eg, pests, mould and dust mites)
- Environmental pollutants (eg, air pollution)
- Secondhand smoke exposure
- Pets and animals
- Strong odours
- Anxiety or strong emotions

TABLE:2 ASTHMA RISK FACTORS [6]

- Personal or family history of atopy: eczema, allergic rhinitis or nasal polyposis
- Family history of asthma
- Exposure to secondhand smoke
- Preterm birth
- Low birth weight
- Obesity
- Poor housing quality/mould and dampness
- Air pollution

MORBIDITY: Asthma is one of the most common major non-communicable conditions and for numerous, has a substantial impact on quality of life. Encyclopedically, asthma is ranked 16th among the leading causes of times lived with disability and 28th among the leading causes of burden of complaint, as measured by disability-adjusted life times. Around 300 million people have asthma worldwide, and it's likely that by 2025 a further 100 million may be affected [7]. There's a large geographical variation in asthma frequency, inflexibility, and mortality.

While asthma frequency is advanced in high income countries, utmost asthma-related mortality occurs in low-middle income countries [8]. Asthma mortality dropped from 0.09 per, 1000 children in 2003 to 0.02 per, 1000 children in 2014, with an average mortality of 0.06 per, 1000 children. Mortality due to respiratory conditions was four times more common in cases with asthma than in the general population of children progressed > 5 times, despite diminishments in asthma-related mortality. [9]

TYPES OF ASTHMA ([10])

In children with asthma, three wheeze phenotypes have been identified 1. flash beforehand gasping; 2. nonatopic gasping; and 3. IgE intermediated (atopic) gasping. The flash gasping phenotype is associated with symptoms that are limited to the first 3 – 5 times of life; it isn't associated with a family history of asthma or antipathetic sensitization. Threat factors for this phenotype include dropped lung function that's diagnosed before any respiratory illness has passed, motherly smoking during gestation, and exposure to other siblings or children at daycare centres. Tenon-atopic gasping phenotype represents a group of children who witness occurrences of gasping up to nonage that aren't associated with atopy or antipathetic sensitization. Rather, the gasping is associated with a viral respiratory infection (particularly with the respiratory syncytial contagion (RSV)) endured in the first 3 times of life. Children with this phenotype tend to have milder asthma than the atopic phenotype. IgE-intermediated (atopic) gasping (also appertained to as the “classic asthma phenotype”) is characterized by patient gasping that's associated with atopy, early antipathetic sensitization, significant loss of lung function in the first times of life, and airway hyperresponsiveness

TABLE:3 CONTRASTING FEATURES OF THE TWO MAJOR TYPES OF ASTHMA.[10]

FEATURE	EXTRINSIC ASTHMA	INTRINSIC ASTHMA
1. Age at onset	In childhood	In adult
2. Personal/family history	Commonly present	Absent
3. Preceding allergic illness (atopy)	Present (e.g. rhinitis, urticaria, eczema)	Absent
4. Allergens	Present (dust, pollens, danders etc)	None
5. Drug hypersensitivity	None	Present (usually to aspirin) Normal
6. Serum IgE level	Elevated	
7. Associated chronic bronchitis, nasal polyps	Absent	Present
8. Emphysema	Unusual	Common

CLINICAL FEATURES

- Paroxysms of dyspnoea
- intermittent occurrences of gasping
- Coughing (particularly at night or in the early morning)
- casket miserliness [18]
- Sleep dislocation

Three different patterns of intermittent wheeze in pediatric cases have been proposed [11], and a fourth was lately described [12]. still, it should be noted that patterns 1 and 2 (listed below) can only be discerned retrospectively and aren't suitable for use when treating the child.

1. flash gasping Children who blow during the first 2 – 3 times of life, but don't blow after the age of 3 times

2. Nonatopic gasping substantially touched off by viral infection and tends to remit latterly in nonage

3. patient asthma gasping associated with the following

- Clinical instantiations of atopy (eczema, antipathetic rhinitis and conjunctivitis, food mislike), blood eosinophilia, and/ or elevated total immunoglobulin E(IgE)

- Specific IgE- intermediated sensitization to foods in immaturity and early nonage, and latterly to common gobbled allergens [13 – 17]
 - Inhalant allergen sensitization previous to 3 times of age, especially with sensitization and high situations of exposure to specific imperishable allergens in the home
 - A maternal history of asthma [14]
4. Severe intermittent gasping [12] occasional acute gasping occurrences associated with the following
- minimum morbidity outside of time of respiratory tract illness
 - Atopic characteristics, including eczema, antipathetic sensitization and supplemental blood eosinophilia [14]

TABLE: 4 CLASSIFICATIONS OF SEVERITY BASED ON SYMPTOMS

MILD	MODERATE	SEVERE
<ul style="list-style-type: none"> ➤ Attacks no more often than once a week ➤ Respond to bronchodilators in 24 to 48 hours ➤ No clinical signs of asthma between episodes ➤ Good exercise tolerance ➤ No sleep interruption owing to asthma ➤ No hyperinflation ➤ Normal chest X ray films ➤ Minimal or no evidence of airway obstruction on PFT ➤ No to minimal degree of increased lung volume. 	<ul style="list-style-type: none"> ➤ Exacerbation of cough and wheezing once a week ➤ Cough and low grade of wheezing between acute episodes ➤ Exercise tolerance diminished ➤ May be up at night because of cough and wheezing ➤ Hyperinflation may be clinically evident ➤ Signs of airway obstruction on PFT ➤ Lung volumes increased 	<ul style="list-style-type: none"> ➤ Daily wheezing ➤ Exacerbations frequent, often severe ➤ Tendency to become “tight” suddenly with cyanosis ➤ May have unconscious or hypoxic seizures ➤ Poor exercise tolerance ➤ Much sleep interruption ➤ Chronic hyperinflation leads to chest deformity ➤ Substantial degree of airway obstruction on PFT ➤ Substantial increase in lung volumes

TABLE :5 NORMAL RESPIRATORY RATE FOR AGE [2]

PATHOPHYSIOLOGY

AGE	Respiratory rate (breaths per minute)
Infant	30–60
Dodder	24–40
Preschooler	22–34
School aged child	18–30
Adolescent	12–16

Extrinsic (atopic, allergic) asthma [10]

This is the most common type of asthma. It generally begins in nonage or in early adult life. utmost cases of this type of asthma have particular and/ or family history of antedating antipathetic conditions similar as rhinitis, urticaria or immature eczema. Acuity to colorful foreign antigenic substances or 'allergens' is generally present in these cases. utmost of these allergens begets ill goods by inhalation e.g. house dust, pollens, beast danders, moulds etc. Occupational asthma stimulated by smothers, feasts and organic and chemical dusts is a variant of foreign asthma. There's increased position of IgE in the serum and positive skin test with the specific off ending gobbled antigen representing an IgE-intermediated type I acuity response which includes an ' acute immediate response ' and a ' late phase response ' Acute immediate response is initiated by IgE- sensitised(mast cells(towel counterparts of circulating basophils) on the mucosal face. Mast cells on degranulation release intercessors like histamine, leukotrienes, prostaglandins, platelet cranking factor and chemotactic factors for eosinophils and neutrophils. The net goods of these intercessors are bronchoconstriction, oedema, mucus hypersecretion and accumulation of eosinophils and neutrophils. Late phase response follows the acute immediate response(and is responsible for the prolonged manifestations of asthma. It's caused by inordinate


mobilisation of blood leucocytes that include basophils besides eosinophils and neutrophils. These affect in farther release of intercessors which accentuate the below- mentioned goods. In addition, seditious injury is caused by neutrophils and by major introductory protein(MBP) of eosinophils


Intrinsic (idiosyncratic, on-atopic) asthma [10]:

This type of asthma develops latterly in adult life with negative particular or family history of mislike, negative skin test and normal serum situations of IgE. utmost of these cases develops typical symptom complex after an upper respiratory tract infection by contagions. Associated nasal polypi and habitual bronchitis are generally present. There are no recognisable allergens but about 10 of cases come hypersensitive to medicines, most specially to small boluses of aspirin (aspirin-sensitive asthma).

Mixed type:[10]

Numerous cases don't easily fit into either of the below two orders and have mixed features of both. Those cases who develop asthma in early life have strong antipathetic element, while those who develop the complaint late tend to be non-allergic. Either type of asthma can be rained by cold, exercise and emotional stress.

Figure:1 [10]**Figure:2 [11]**



DIAGNOSIS:

➤ opinion is made primarily by history of intermittent occurrences of coughing, gasping, chest tightness or short of breath and confirmational spirometry [21].

➤ History of exercise or cold air pouring dyspnea during specific seasons suggests asthma

➤ Pulmonary function test or lung function tests are useful in assessing the functional status of the respiratory system in both physiological and pathological conditions. It's grounded on the dimension of volume of air breathed in and out in quiet breathing and forced breathing [22]

➤ likewise, children with asthma and food disinclinations were estimated to have further eosinophils in foam than children with asthma without food disinclinations.

➤ Analysis of exhaled breath condensate is another invasive system to reflect airway inflammation.

Medical tests for asthma include

Spirometry: Spirometry is a common test that measures how much air you inhale, how much air you exhale, and how quickly you exhale to determine how well your lungs serve.

Spirometry is used to diagnose asthma, COPD, and other respiratory diseases. A spirometry test allows you to breathe into a tube connected to a spirometer

unit. A nanny, a technician, or your croaker will give you clear instructions before you perform the test.

Spirometry way followed by

- You'll probably be seated during the test
- To keep your nostrils closed, a clip will be put on your nose.
- You'll be take a deep breath and breath out as hard as you can for several seconds in to the tube. It's important that your lips form a tight seal around the tube to help air from escaping.
- You'll need to do the test atleast 3 times to make sure your results are fairly consistant if there's variations repeat the test again
- The entire process requires lower than 15 twinkles.

Peak expiratory flow: Peak inflow measures may be used to assess lung function in children over 5 times with asthma, but symptom monitoring is the most dependable assessment of asthma control. They're stylish used for short ages to assess these variety of asthma and to cover response to treatment; nonstop use of peak inflow measures may abstract from compliance with inhalers [23].

The peak expiratory inflow, also called peak expiratory inflow rate (PEFR), is a person's maximum speed of expiration, as measured with a device called peak inflow cadence, you strongly exhale into the tube to measure the force of air you can expend out of your lungs.

Peak expiratory inflow rate (PEFR) is the outside inflow rate generated during a forceful exhalation, starting from full lung affectation. PEFR primarily reflects large airway inflow and depends on the voluntary trouble and muscular strength of the case.

Pulmonary function test

Pulmonary function testing is an important tool in the operation of asthma used to determine asthma inflexibility, along with clinical symptoms.

Short acting bronchodilator remedy was withheld for at 8 hours and longacting bronchodilator remedy for atleast 24 hours. palpitation oximetry was recorded in the children with asthma. PFTs are noninvasive tests that show how well lungs are working. The tests measure lung volume, capacity, rates of inflow, and gas exchange.

Chest x-ray


Chest radiographic imaging is an important tool in the examination of cases with an exacerbation of asthma, casket radiography is the original imaging evaluation in utmost individualities with symptoms of asthma. It generally is more useful in the original opinion of bronchial asthma than in the discovery of exacerbations [24]

TREATMENT

Oxygen:

Oxygen must be considered as a drug in a situation of acute asthma, reducing hypoxic pulmonary vasoconstriction and interfering with the ventilation-perfusion mismatch characteristic for severe bronchoconstriction [26]. No controlled studies have evaluated which level of oxygen saturation that is adequate during an acute asthma attack, but recent guidelines recommend that oxygen saturation in children should be kept above 95% [27].

A stepwise algorithm for the treatment of asthma:



A simplified, stepwise algorithm for the treatment of asthma. ICS: inhaled corticosteroid; LTRA: leukotriene receptor antagonist; LABA: long-acting beta2-agonist; IgE: immunoglobulin E Note: Treatments can be used individually or in any combination

Oral corticosteroids:

Although systemic corticosteroid therapy is listed as a treatment option for severe asthma management, there is no protocol to guide this therapy in children.[28] Oral steroid therapy has been shown to be an effective treatment of acute asthma [29,30]and equal in efficacy when compared with intravenous therapy in pediatric patients [31]. A short-term course of systemic corticosteroids can be used to achieve asthma control.[32] The lowest effective dose should be used, and the dose should be gradually decreased to the lowest dose that can maintain asthma control.[30] The few trials in pediatric patients that have evaluated use of inhaled corticosteroids as an alternative to systemic corticosteroids for acute asthma have yielded mixed results [33,34]. Meanwhile, other non-steroid medications such as biological therapies or long-acting anticholinergic drugs need to be considered for severe asthma management. Frequent use of systemic steroids increases the risks for adverse events including adrenal suppression, obesity, high blood pressures, bone fractures and osteoporosis [28]

Short acting bronchodilator:

Inhaled short-acting beta-agonists (eg, salbutamol) should always be readily available for asthma patients for when they experience asthma symptoms. Inhaled beta-agonists are the first-line treatment for relieving symptoms of acute asthma [35]. Aerosolized β_2 -adrenergic agonist therapy is part of the home regimen for daily management of asthma symptoms and also as initial treatment of acute exacerbations; these commonly are firstline agents in the ED.[36] β_2 receptors are found in the airways, heart, blood vessels, skeletal muscle, uterus, liver, pancreas, and kidney.[37,38] In the airways, β_2 -adrenergic agonists cause smooth muscle relaxation, decrease the amount of hyperreactivity, improve mucociliary clearance, and reduce airway edema.School-aged children should always carry a short-acting beta-agonist in their school bags and an additional short-acting betaagonist should be kept on the school premises. As pressurized metered dose inhalers (pMDIs) should be used in conjunction with valved holding chambers, older children and adolescents often prefer taking smaller, unobtrusive dry powder beta-agonist inhalers to school. In such situations, it is important that a pMDI should also be

available at the school in case of a severe asthma episode when the child may have difficulty using a dry powder inhaler. Anticholinergics such as ipratropium bromide offer little benefit as an add-on bronchodilator treatment during acute asthma exacerbations and hence have a limited role in treating bronchoconstriction in children.[39] chronic, short-acting anticholinergic bronchodilator therapy is not recommended for use in children [40].

Combination ics/labA inhalers

The combination of a LABA and ICS has been shown to be highly effective in reducing asthma symptoms and exacerbations, and is the preferred treatment option in adolescents or adults whose asthma is inadequately controlled on low-dose ICS therapy, or in children over 6 years of age who are uncontrolled on moderate ICS doses. combination ICS/LABA inhalers are preferred because they preclude use of the LABA without anICS, are more convenient and may enhance patient adherence. Combination budesonide/formoterol has been approved for use as a single inhaler for both daily maintenance (controller) and reliever therapy in individuals 12 years of age and older.[40]

Theophylline:

Theophylline is an oral bronchodilator with modest anti-inflammatory effects. Given its narrow therapeutic window and frequent adverse events (e.g., gastrointestinal symptoms, loose stools, seizures, cardiac arrhythmias, nausea and vomiting), its use is generally reserved for patients over 12 years of age who are intolerant to or continue to be symptomatic despite other add-on therapies [40].

Long-acting muscarinic receptor antagonists

The LAMA, tiotropium, administered by mist inhaler can be used as add-on therapy for patients with a history of exacerbations despite treatment with ICS/LABA combination therapy. It is only indicated for patients 12 years of age and older.[41]

CONCLUSION:

During last decades, asthma prevalence has been increasing worldwide. As a chronic condition that usually starts in early childhood, it imposes a high lifetime burden on individuals, their caregivers and the community. Heterogenicity, Social and Environmental factor are the most important reason for the cause of asthma in children. In order to improve outcomes accurate diagnosis and management are essential. Due to heterogeneity of asthma characteristics, treatment decisions should be critically made. Symptoms control of asthmatic patients should be closely monitored, as well as risk

factors and frequency of exacerbations, and the response to treatment should be regularly monitored and reviewed by specialists. Inhaled Corticosteroids are the most effective treatment for the control of asthma attacks. Ongoing monitoring of adherence to the treatment and asthma control by spirometry must be encouraged. Paediatric asthma are currently poor and many deaths are preventable.

REFERENCES:

- Ibrahim C, Singh K, Tsai G, Huang D, Mazza J, Rotenberg B, Kim H, Moote DW. A retrospective study of the clinical benefit from acetylsalicylic acid desensitization in patients with nasal polyposis and asthma. *Allergy, Asthma & Clinical Immunology*. 2014 Dec;10(1):1-6.
- Corrales AY, Soto-Martinez M, Starr M. Management of severe asthma in children. *Australian family physician*. 2011 Jan;40(1/2):35-8.
- Sachdev A, Gupta N. Acute severe asthma in children.
- Mohan H. Textbook of pathology. Jaypee Brothers Medical Publishers; 2018 Nov 30. Bronchial asthma:463
- Subbarao P, Mandhane PJ, Sears MR. Asthma: epidemiology, etiology and risk factors. *Cmaj*. 2009 Oct 27;181(9):E181-90.
- Martin J, Townshend J, Brodlie M. Diagnosis and management of asthma in children. *BMJ paediatrics open*. 2022;6(1).
- Network GA. The global asthma report 2014. Auckland, New Zealand. 2014;769:28-36.
- To T, Stanojevic S, Moores G, Gershon AS, Bateman E, Cruz AA, Boulet LP. Global asthma prevalence in adults: findings from the cross-sectional world health survey <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353191>. 2012.
- Sol IS, Jang H, Noh J, Kim SY, Kim MJ, Kim YH, Kim C, Sohn MH, Kim KW. Mortality and morbidity in children with asthma: A nationwide study in Korea. *Respiratory Medicine*. 2021 Feb 1;177:106306.
- Mohan H. Textbook of pathology. Jaypee Brothers Medical Publishers; 2018 Nov 30. Bronchial asthma:464
- Robbins KV. Cotran Pathologic basis of Disease 9th edition/Kumar V., Abbas AK, Aster JC-Canada.681
- Sean Holt, MBBS, a Matthew Masoli, MRCP, b and Richard Beasley, DM, b, c Wellington, New Zealand, and Southampton, United Kingdom, increasing compliance with inhaled corticosteroids through the use of combination therapy; review and feature articles.
- Ajay Punj, Ashish Prakash and Ashu Bhasin, Department of Pediatrics, Subharti Institute of Medical Sciences, Meerut, U.P. India, Levosalbutamol vs Racemic Salbutamol in the Treatment of Acute Exacerbation of Asthma; [Indian J Pediatr 2009; 76 (11) : 1131-1135]
- Sayid M Barkiya¹, Veena Kumari², Venugopal N², Abdul aseeze³ - Effects of Aerosolized Levosalbutamol Verses Salbutamol on Serum Potassium Level and Heart Rate in Children with Acute Exacerbation of Asthma; *International Journal of Scientific Study* | February 2016 | Vol 3 | Issue 11, pgno 223-227.
- L. B. Bacharier¹, A. Boner², K.-H. Carlsen³, et al Review article-Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report; _ 2008 The Authors journal compilation _ 2008 Blackwell Munksgaard; 5–34.
- Jaclyn Quirt, Kyla. J. Hildebrand, et al, Review allergy, asthma and clinical immunology; Quirt et al. *Allergy Asthma Clin Immunol* 2018, 14(Suppl 2):50.
- Management of Asthma in Children JAMES P. KEMP, M.D., University of California School of Medicine, San Diego, California JUDITH A. KEMP, D.O., San Diego, California (*Am Fam Physician* 2001;63:1341-8,1353-4.);
- Faiqa Qureshi, MD, Arno Zaritsky, MD, and Michael P. Poirier, MD; Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma; (*J Pediatr* 2001;139:20-6)
- Elliot F. Ellis, M.D. Buffalo, N.Y.-Asthma in childhood ; (*J ALLERGY CLIN IMMUNOL* 72.526539, 1983. 20. Wim. M. Aalderen, department of pediatric diseases and allergy; Review article childhood
- Kumar V, Abbas AK, Aster JC. Robbins basic pathology e-book. Elsevier Health Sciences; 2017 Mar 8. Asthma:504
- Pharmacotherapy ,joseph t dipiro(pg no;823-834)
9. R. DAHL, et al-Monitoring of bronchial asthma; *RESPIRATORY MEDICINE* (1997) 91, 581-586
- Pubmed: Diagnosis of bronchial asthma
- LARS J GRIMM, MD, MHS, et al – Asthma imaging and diagnosis(dec28,2020)Medscape.com
- Rodriguez-Roisin R. Acute severe asthma: pathophysiology and pathobiology of gas exchange abnormalities. *European Respiratory Journal*. 1997 Jun 1;10(6):1359-71.
- Øymar K, Halvorsen T. Emergency presentation and management of acute severe asthma in children. *Scandinavian Journal of Trauma*,

- Resuscitation and Emergency Medicine. 2009 Dec;17(1):1-1.
27. Allen DB. Effects of inhaled steroids on growth, bone metabolism and adrenal function. *Expert Rev Respir Med* 2007;1:65-74.
 28. Rowe BH, Keller JL, Oxman AD. Effectiveness of steroid therapy in acute exacerbations of asthma: a meta-analysis. *Am J Emerg Med* 1992;10:301- 10.
 29. Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. *Pediatrics* 1993;92:513-8.
 30. Barnett PLJ, Caputo GL, Baskin M, Kupperman N. Intravenous versus oral corticosteroids in the management of acute asthma in children. *Ann Emerg Med* 1997;29:212-7.
 31. Barsky EE, Giancola LM, Baxi SN, Gaffin JM. A practical approach to severe asthma in children. *Ann Am Thorac Soc* 2018;15:399-408
 32. Pedersen S. Do inhaled corticosteroids inhibit growth in children? *Am J Respir Crit Care Med* 2001;164:521-35.
 33. Schuh S, Reisman J, Alsherhri M, Dupuis A, Corey M, Arseneault R, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. *N Engl J Med* 2000;343:689-94.
 34. Engelhardt A. Pharmacology and toxicology of Atrovent. *Scand J Respir Dis* 1979;103:110-5.
 35. Schultz A, Martin AC. Outpatient management of asthma in children. *Clinical Medicine Insights: Pediatrics*. 2013 Jan;7:CMPed-S7867
 36. National Asthma Education and Prevention Program Expert Panel report 2: guidelines for the diagnosis and management of asthma. NIH—publication no. 97-4051. Bethesda, MD: US Department of Health and Human Services, 1997.
 37. Lipworth BJ. Risk versus benefits of inhaled β_2 -agonists in the management of asthma. *Drug Safety* 1992;7:54-70.
 38. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, eds. *Goodman & Gilman's the pharmacological basis of therapeutics*. 9th ed. New York: McGraw-Hill, 1996;199-248.
 39. Goggin N, Macarthur C, Parkin PC. Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. *Arch Pediatr Adolesc Med*. 2001;155(12):1329–34.
 40. Loughheed MD, Lemièrè C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, Licskai C, Rowe BH, Bowie D, Becker A, Boulet LP: Canadian Thoracic Society asthma management continuum: 2010 consensus summary for children six years of age and over, and adults. *Can Respir J* 2010,17:15-24.
 41. Quirt A, Hildebrand KJ, Mazza J, Noya F, Kim H. *Allergy Asthma Clin*.